Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice

Overview

Journal Front Pharmacol

Date 2020 Apr 24

PMID 32322210

Citations 12

Authors

Jia Zhang

Weiyi Wang

Yuan Zhou

Jing Yang

Jingli Xu

Zhiyuan Xu

Beihua Xu

Li Yan

Xiang-Dong Cheng

Minghua Li

Jiang-Jiang Qin

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is an aggressive and fatal disease with high incidences of metastasis and recurrence. However, there are no effective treatment options for the majority of PC patients, especially for those with locally advanced tumors and metastatic diseases. Therefore, it is urgently needed to develop safe and effective anti-PC therapeutic agents. We have recently identified a novel marine-derived natural product terphenyllin with potent anti-PC activity. The present study was designed to investigate the efficacy and mechanisms of action of terphenyllin in several human PC cell lines and an orthotopic PC mouse model. The results showed that terphenyllin significantly inhibited the viability of all PC cell lines with minimal effects on a normal human pancreatic cell line (HPNE). We next demonstrated the effects of terphenyllin on colony formation, apoptosis, migration, and invasion in both Panc1 and HPAC cell lines in a concentration-dependent manner. Terphenyllin also suppressed the tumor growth and metastasis in the Panc1 orthotopic mouse model. We further showed the profound effects of terphenyllin on the expression of apoptosis-associated proteins, including Bax, Bad, Puma, Bim, Bcl-2, phos-Bcl-2 (Ser70), Bcl-xL, caspase 7, and PARP, which contributed to its anti-PC activity. In summary, terphenyllin suppressed the PC cell growth and metastasis and and may be developed as an anti-PC therapeutic agent in the future.

Citing Articles

Terphenyllin induces CASP3-dependent apoptosis and pyroptosis in A375 cells through upregulation of p53.

Wu W, Wu M, Dai T, Ke L, Shi Y, Hu J Cell Commun Signal. 2024; 22(1):409.

PMID: 39169379 PMC: 11337594. DOI: 10.1186/s12964-024-01784-7.

The role of proteasomes in tumorigenesis.

Zhou X, Xu R, Wu Y, Zhou L, Xiang T Genes Dis. 2024; 11(4):101070.

PMID: 38523673 PMC: 10958230. DOI: 10.1016/j.gendis.2023.06.037.

Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer.

Xun J, Ohtsuka H, Hirose K, Douchi D, Nakayama S, Ishida M BMC Cancer. 2023; 23(1):835.

PMID: 37674118 PMC: 10481509. DOI: 10.1186/s12885-023-11294-3.

Active Ingredients from Chinese Medicine for Combination Cancer Therapy.

Wang X, Li J, Chen R, Li T, Chen M Int J Biol Sci. 2023; 19(11):3499-3525.

PMID: 37497002 PMC: 10367560. DOI: 10.7150/ijbs.77720.

Platycodin-D exerts its anti-cancer effect by promoting c-Myc protein ubiquitination and degradation in gastric cancer.

Xu Q, Pan G, Wang Z, Wang L, Tang Y, Dong J Front Pharmacol. 2023; 14:1138658.

PMID: 36950011 PMC: 10025306. DOI: 10.3389/fphar.2023.1138658.

References

Wang W, Qin J, Li X, Tao G, Wang Q, Wu X . Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018; 39(8):1026-1036. PMC: 6067121. DOI: 10.1093/carcin/bgy063. View

Wang W, Zhang X, Qin J, Voruganti S, Nag S, Wang M . Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One. 2012; 7(7):e41586. PMC: 3402429. DOI: 10.1371/journal.pone.0041586. View

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson C, Biankin A . Pancreatic cancer. Nat Rev Dis Primers. 2016; 2:16022. DOI: 10.1038/nrdp.2016.22. View

Karandish F, Mallik S . Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer. 2016; 8(Suppl 1):27-35. PMC: 4847554. DOI: 10.4137/BiC.s34414. View

Nag S, Qin J, Srivenugopal K, Wang M, Zhang R . The MDM2-p53 pathway revisited. J Biomed Res. 2013; 27(4):254-71. PMC: 3721034. DOI: 10.7555/JBR.27.20130030. View

Qin J, Wang W, Zhang R . Novel natural product therapeutics targeting both inflammation and cancer. Chin J Nat Med. 2017; 15(6):401-416. PMC: 6663108. DOI: 10.1016/S1875-5364(17)30062-6. View

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View

Waters A, Der C . KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2017; 8(9). PMC: 5995645. DOI: 10.1101/cshperspect.a031435. View

Lambert A, Gavoille C, Conroy T . Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol. 2017; 10(8):631-645. PMC: 5557187. DOI: 10.1177/1756283X17713879. View

10.

McBride A, Bonafede M, Cai Q, Princic N, Tran O, Pelletier C . Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Expert Rev Clin Pharmacol. 2017; 10(10):1153-1160. DOI: 10.1080/17512433.2017.1365598. View

11.

Nag S, Qin J, Wang W, Wang M, Wang H, Zhang R . Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol. 2012; 3:25. PMC: 3289390. DOI: 10.3389/fphar.2012.00025. View

12.

Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y . A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine. 2017; 22:58-67. PMC: 5552238. DOI: 10.1016/j.ebiom.2017.07.014. View

13.

Wang W, Liao Y, Tang C, Huang X, Luo Z, Chen J . Cytotoxic and Antibacterial Compounds from the Coral-Derived Fungus Aspergillus tritici SP2-8-1. Mar Drugs. 2017; 15(11). PMC: 5706038. DOI: 10.3390/md15110348. View

14.

Voruganti S, Xu F, Qin J, Guo Y, Sarkar S, Gao M . RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Lett. 2015; 369(2):386-95. PMC: 4733564. DOI: 10.1016/j.canlet.2015.09.003. View

15.

Qin J, Li X, Wang W, Zi X, Zhang R . Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2018; 8:917. PMC: 5735069. DOI: 10.3389/fphar.2017.00917. View

16.

Qi S, Cheng G, Cheng X, Xu Z, Xu B, Zhang W . Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?. Front Cell Dev Biol. 2020; 8:233. PMC: 7142254. DOI: 10.3389/fcell.2020.00233. View

17.

Qin J, Wang W, Voruganti S, Wang H, Zhang W, Zhang R . Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget. 2015; 6(5):2623-40. PMC: 4413606. DOI: 10.18632/oncotarget.3098. View

18.

Mosquera C, Maglic D, Zervos E . Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. Cancer Genet. 2016; 209(12):567-581. DOI: 10.1016/j.cancergen.2016.07.003. View

19.

Werner J, Combs S, Springfeld C, Hartwig W, Hackert T, Buchler M . Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013; 10(6):323-33. DOI: 10.1038/nrclinonc.2013.66. View

20.

Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J . KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers (Basel). 2017; 9(5). PMC: 5447952. DOI: 10.3390/cancers9050042. View